arrow
M

Michael S. Anglesio

university of british columbia and bc cancer and vancouver general hospital
H指数:53
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma

BRCA缺陷性输卵管卵巢高级别浆液性癌的生存临床病理及分子预测因子

2026-04-010
OAAI
M2 Macrophages are Major Mediators of Germline Risk of Endometriosis and Explain Pleiotropy With Comorbid Traits

M2巨噬细胞是子宫内膜异位症种系风险的主要介导因子,并解释了与合并症表型的遗传多效性。

2025-09-120
OAAI
WERF Endometriosis Phenome and Biobanking Harmonisation Project for Experimental Models in Endometriosis Research (EPHect-EM-Homologous): homologous rodent models
2025-01-010
PRE
KRAS mutations and endometriosis burden of disease

KRAS突变与子宫内膜异位症疾病负担

2023-03-2812
OAAI
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

p53和卵巢癌生存: 卵巢肿瘤组织分析联盟研究

2023-03-2210
OAAI
Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
2023-02-150
OA
Single-cell transcriptomic analysis of endometriosis

子宫内膜异位症的单细胞转录组学分析

2023-01-0948
OA
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

CCNE1与输卵管卵巢高级别浆液性癌患者的生存: 卵巢肿瘤组织分析联盟研究

CANCER
IF5.1
2022-12-2614
OAAI
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

高级别浆液性卵巢癌中FOXJ1蛋白表达增加与总生存期改善相关: 卵巢肿瘤组织分析联盟研究

2022-11-023
OA
The proteome of clear cell ovarian carcinoma

卵巢透明细胞癌的蛋白质组

2022-10-149
OA
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2022-10-0711
OAAI
Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
2022-07-1136
OAAI
Multi-modal immune profiling of mucinous ovarian carcinoma: analysis from the Ovarian Tumor Tissue Analysis/Multidisciplinary Ovarian Cancer Outcomes Group consortia
2022-05-010
PRE
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas

经过验证的生物标志物检测证实,ARID1A丢失与MMR缺乏,CD8 TIL浸润混淆,并且在子宫内膜异位症相关的卵巢癌中没有独立的预后价值。

2022-02-0721
OA